Shitara Y[au] - Search Results

Year	Number of Results
1981	1
1983	1
1994	3
1995	3
1996	2
1997	1
1998	2
1999	3
2000	6
2001	4
2002	3
2003	2
2004	4
2005	1
2006	4
2007	2
2008	5
2009	3
2010	4
2011	2
2012	9
2013	10
2014	2
2016	4
2017	6
2018	3
2019	2
2020	3
2021	3
2022	1

1

Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences.

Oga EF, Sekine S, Shitara Y, Horie T. Oga EF, et al. Among authors: shitara y. Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):93-108. doi: 10.1007/s13318-015-0296-z. Eur J Drug Metab Pharmacokinet. 2016. PMID: 26311243 Review.

2

A term infant with fetal giant meconium hydrocele caused by meconium peritonitis.

Shitara Y, Watanabe E, Takahashi N. Shitara Y, et al. Pediatr Neonatol. 2021 Jul;62(4):445-446. doi: 10.1016/j.pedneo.2021.03.006. Epub 2021 Mar 18. Pediatr Neonatol. 2021. PMID: 33931345 Free article. No abstract available.

3

Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.

Shitara Y. Shitara Y. Drug Metab Pharmacokinet. 2011 Jun;26(3):220-7. doi: 10.2133/dmpk.DMPK-10-RV-094. Epub 2011 Feb 1. Drug Metab Pharmacokinet. 2011. PMID: 21297316 Free article. Review.

4

Case of spinal muscular atrophy type 0 with mild prognosis.

Kitaoka H, Shitara Y, Uchida Y, Kondo U, Omori I. Kitaoka H, et al. Among authors: shitara y. Pediatr Int. 2020 Jan;62(1):106-107. doi: 10.1111/ped.14047. Epub 2020 Jan 9. Pediatr Int. 2020. PMID: 31916364 No abstract available.

5

Improved Prediction of the Drug-Drug Interactions of Pemafibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemafibrate and Inhibition Constants With Preincubation Against OATP1B.

Park JE, Shitara Y, Lee W, Morita S, Sahi J, Toshimoto K, Sugiyama Y. Park JE, et al. Among authors: shitara y. J Pharm Sci. 2021 Jan;110(1):517-528. doi: 10.1016/j.xphs.2020.10.016. Epub 2020 Oct 13. J Pharm Sci. 2021. PMID: 33058894

6

Case Report: Treatment of Extremely Preterm Infants With Birthweight Below 300 g: Case Series.

Shitara Y, Kakiuchi S, Mukai T, Kashima K, Kato M, Takahashi N. Shitara Y, et al. Front Pediatr. 2021 Dec 6;9:758683. doi: 10.3389/fped.2021.758683. eCollection 2021. Front Pediatr. 2021. PMID: 34938697 Free PMC article.

7

Transporters as a determinant of drug clearance and tissue distribution.

Shitara Y, Horie T, Sugiyama Y. Shitara Y, et al. Eur J Pharm Sci. 2006 Apr;27(5):425-46. doi: 10.1016/j.ejps.2005.12.003. Epub 2006 Feb 20. Eur J Pharm Sci. 2006. PMID: 16488580 Review.

8

Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions.

Shitara Y, Sugiyama Y. Shitara Y, et al. Pharmacol Ther. 2017 Sep;177:67-80. doi: 10.1016/j.pharmthera.2017.02.042. Epub 2017 Feb 27. Pharmacol Ther. 2017. PMID: 28249706 Review.

9

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs.

Shitara Y, Sato H, Sugiyama Y. Shitara Y, et al. Annu Rev Pharmacol Toxicol. 2005;45:689-723. doi: 10.1146/annurev.pharmtox.44.101802.121444. Annu Rev Pharmacol Toxicol. 2005. PMID: 15822193 Review.

10

Non-surgical intervention for open myelomeningocele in an infant with trisomy 18.

Shitara Y, Oida N, Kondo U, Kushima R, Omori I. Shitara Y, et al. Pediatr Int. 2020 Apr;62(4):496-497. doi: 10.1111/ped.14094. Epub 2020 Mar 24. Pediatr Int. 2020. PMID: 32212200 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results